MAIA Biotechnology, Inc. reported on June 2, 2025, that it presented data from its Phase 2 clinical trial for a lung cancer treatment at the ASCO Annual Meeting on May 31, 2025, with results to be posted on its website. The filing includes a poster and a presentation summarizing its business and the trial results.